STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
radiology

AstraZeneca to Acquire Fusion Pharmaceuticals: Pioneering Precision Cancer Treatments

byLiliana Vida
March 19, 2024
in Biotechnology, Large-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Acquisition Marks AstraZeneca’s Commitment to Advancing Cancer Care with Radioconjugates

AstraZeneca, (AZN) a leading global biopharmaceutical company, has announced a definitive agreement to acquire Fusion Pharmaceuticals Inc., (FUSN) a clinical-stage oncology company renowned for its development of next-generation radioconjugates as precision medicines. This strategic move underscores AstraZeneca’s dedication to revolutionizing cancer treatment and outcomes by replacing conventional regimens like chemotherapy and radiotherapy with more targeted therapies.

Radioconjugates (RCs) have emerged as a promising modality in cancer treatment, offering the potential to deliver radioactive isotopes directly to cancer cells with precision. Fusion’s innovative approach utilizes molecules such as antibodies, peptides, or small molecules to precisely target cancer cells, minimizing damage to healthy tissue and expanding the reach of treatment to tumors previously inaccessible through traditional methods.

The acquisition will augment AstraZeneca’s leading oncology portfolio with Fusion’s pipeline of RCs, including its advanced program FPI-2265, designed to address metastatic castration-resistant prostate cancer (mCRPC). FPI-2265 targets prostate-specific membrane antigen (PSMA), a protein highly expressed in mCRPC, and is currently undergoing Phase 2 trials.

With this acquisition, AstraZeneca gains access to Fusion’s expertise in radioconjugates, including pioneering research and development, manufacturing capabilities, and the supply chain for actinium-based RCs. This strategic collaboration reinforces AstraZeneca’s commitment to advancing cancer care and underscores its position as a leader in the oncology space.

The transaction, valued at approximately $2 billion, represents a significant premium to Fusion’s market price and underscores AstraZeneca’s confidence in Fusion’s innovative approach to cancer therapy. The acquisition is expected to close in the second quarter of 2024, subject to regulatory approvals and customary closing conditions, marking a milestone in the journey towards transformative cancer treatments.

Read the original press release:here

You might like this article:Boeing’s Defense Suppliers Improve On-Time Deliveries Despite Supply Chain Strain

Previous Post

Boeing’s Defense Suppliers Improve On-Time Deliveries Despite Supply Chain Strain

Next Post

MicroStrategy Boosts Bitcoin Holdings, Now Owns 1% of Supply

Related Posts

Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock

byLuca Blaumann
August 7, 2025
0

Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter...

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

byLuca Blaumann
August 6, 2025
0

Cosmetics giant sees 30% profit drop as China duties weigh on bottom line, even as revenue and product innovation remain...

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

byLuca Blaumann
August 5, 2025
0

Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...

Next Post
bitcoin-1

MicroStrategy Boosts Bitcoin Holdings, Now Owns 1% of Supply

Latest News

Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock

Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

Based on Your Interest

tesla
Artificial Intelligence

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

August 4, 2025
evtol
Aerospace & Defense

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

August 4, 2025
trading-chart-2
Large-Cap

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

July 30, 2025

Recommended

Aerospace & Defense

Palo Alto Networks Eyes $20B Deal for CyberArk

July 29, 2025
Ecommerece

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025
Entertainment

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

July 25, 2025
Aerospace & Defense

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

July 24, 2025
Large-Cap

Intel Beats on Revenue, Misses on Earnings; Cuts Workforce by 15%

July 24, 2025
Stoxpo

Follow us on social media:

Highlights

  • Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock
  • Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light
  • Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations
  • Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast
  • Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock

August 7, 2025

Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light

August 7, 2025

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

August 6, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?